FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues

Alba Font‐Tello(Dana-Farber Cancer Institute), Henry W. Long(Dana-Farber Cancer Institute), Paloma Cejas(Dana-Farber Cancer Institute), Leonie S. Young(Unknown), Myles Brown(Harvard University), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Ana Lako(Brigham and Women's Hospital), Len Taing(Dana-Farber Cancer Institute), Yingtian Xie(Dana-Farber Cancer Institute), Nikolas Kesten(Dana-Farber Cancer Institute), Anis Hamid(Harvard University), F. Steven Hodi(Harvard University), Joaquim Bellmunt(Dana-Farber Cancer Institute), Christopher J. Sweeney(The University of Adelaide), Damir Varešlija(University College Dublin), Evisa Gjini(Brigham and Women's Hospital)
Nature Protocols
June 26, 2020
10.1038/s41596-020-0340-6
Cited by 36

Related Papers

Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k